12:00 AM
Mar 25, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Rescula unoprostone isopropyl: Phase III started

R-Tech began a double-blind, placebo-controlled, Japanese Phase III trial to evaluate 0.15% UF-021 for 52 weeks in about 180 patients. The trial includes a 52-week open-label study following the treatment period. The Japan Science and Technology Agency (Saitama, Japan) is funding the trial through its Adaptable and Seamless...

Read the full 220 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >